HIV prevalence in Africa, specifically in Southern region is very high as compared to North African region. Approximately 1 out of 4 is suffering from HIV. Southern and Eastern region of Africa has one of the highest prevalence rate of HIV, about 19 million people have HIV. While HIV prevalence is low in North Africa but the number of cases of HIV are increasing rapidly. There is no cure for HIV but drugs manufacturing companies are investing huge money in R&D to develop drugs for HIV.
Over 3000 patients were died in sub Saharan Africa due to HIV in 2015. Following 10 countries from Africa consists of 80% of total HIV burden which are South Africa, Kenya, Malawi, Ethiopia, Mozambique, United Republic of Tanzania, Nigeria, Uganda, Zimbabwe and Zambia.

The global HIV Diagnosis & Treatment market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on HIV Diagnosis & Treatment volume and value at global level, regional level and company level. From a global perspective, this report represents overall HIV Diagnosis & Treatment market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of HIV Diagnosis & Treatment in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their HIV Diagnosis & Treatment manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Abbott Laboratories
Boehringer Ingelheim
Bristol-Myers Squibb
Cipla
F. Hoffmann-La Roche
Gilead
GlaxoSmithKline
Johnson & Johnson

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
ELISA Test
Saliva Tests
Viral Load Test
Western Blot
Others

Segment by Application
Hospitals
Clinics